EFFICACY AND SAFETY OF IPTACOPAN IN PARTICIPANTS WITH C3 GLOMERULOPATHY: C3G EXTENSION TRIAL INTERIM RESULTS FROM THE PHASE 3 APPEAR-C3G PARTICIPANTS

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/db346290440219da110920149409d044.pdf
EFFICACY AND SAFETY OF IPTACOPAN IN PARTICIPANTS WITH C3 GLOMERULOPATHY: C3G EXTENSION TRIAL INTERIM RESULTS FROM THE PHASE 3 APPEAR-C3G PARTICIPANTS

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Carla M.
Nester
Carla M. Nester cnester@uiowa.edu Stead Family Children’s Hospital University of Iowa Iowa United States *
Richard J.H. Smith richard-smith@uiowa.edu Carver College of Medicine University of Iowa Iowa United States -
David Kavanagh david.kavanagh@newcastle.ac.uk Translational and Clinical Research Institute Newcastle University Newcastle upon Tyne United Kingdom - National Renal Complement Therapeutics Centre Royal Victoria Infirmary Newcastle upon Tyne United Kingdom
Marina Vivarelli marina.vivarelli@opbg.net Bambino Gesù Children's Hospital IRCCS Rome Italy -
Giuseppe Remuzzi giuseppe.remuzzi@marionegri.it Istituto di Ricerche Farmacologiche Mario Negri IRCCS Bergamo Italy -
Ming-Hui Zhao mhzhao@bjmu.edu.cn Peking University First Hospital Beijing Beijing China -
Edwin K.S. Wong Edwin.wong1@nhs.net National Renal Complement Therapeutics Centre Royal Victoria Infirmary Newcastle upon Tyne United Kingdom -
Yaqin Wang yaqin.wang@novartis.com Novartis Pharmaceuticals Corporation East Hanover New Jersey United States -
Rubeen K. Israni rubeen.israni@novartis.com Novartis Pharmaceuticals Corporation East Hanover New Jersey United States -
Hari V. Kalluri hari.kalluri@novartis.com Novartis Pharmaceuticals Corporation East Hanover New Jersey United States -
Induja Krishnan induja.krishnan@novartis.com Novartis Pharmaceuticals Corporation East Hanover New Jersey United States -
Jean Grisouard jean-1.grisouard@novartis.com Novartis Pharma AG Basel Basel Switzerland -
Andrew S. Bomback asb68@cumc.columbia.edu David Kock Jr Glomerular Kidney Center Columbia University Irving Medical Center New York United States -
-
-